Neuropace Historical Financial Ratios

NPCE Stock

USD 12.30 0.28 2.33%

Neuropace is lately reporting on over 96 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 69.4 will help investors to properly organize and evaluate Neuropace financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

About Neuropace Financial Ratios Analysis

NeuropaceFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Neuropace investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Neuropace financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Neuropace history.

Neuropace Financial Ratios Chart

At present, Neuropace's Days Sales Outstanding is projected to slightly grow based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 0.29, whereas Free Cash Flow Yield is forecasted to decline to (0.06).

Days Sales Outstanding Free Cash Flow Yield Operating Cash Flow Per Share Capex To Depreciation Pb Ratio

Add Fundamental

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most ratios from Neuropace's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Neuropace current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.At present, Neuropace's Days Sales Outstanding is projected to slightly grow based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 0.29, whereas Free Cash Flow Yield is forecasted to decline to (0.06).

	2022	2023	2024	2025 (projected)
Payables Turnover	6.07	7.42	7.05	9.56
Days Of Inventory On Hand	272.12	236.61	234.57	273.68

Payables Turnover Days Of Inventory On Hand

Neuropace fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.72	-0.25	-0.96	0.55	-0.22	0.74	-0.72	0.98	-0.23	-0.89	-0.31	-0.41	0.5	0.96	0.57	-0.85	-0.86	0.69	-0.55	-0.84	-0.9	0.74	0.87	-0.83	-0.83
Ptb Ratio	-0.72		0.3	0.64	0.01	0.73	-0.7	1.0	-0.63	0.74	0.67	0.11	0.86	-0.4	-0.6	-0.71	0.41	0.3	-0.13	0.64	0.28	0.48	-0.54	-0.96	0.23	0.23
Days Sales Outstanding	-0.25	0.3		0.09	0.08	0.44	-0.7	0.3	-0.21	0.45	0.54	0.28	0.43	-0.48	-0.11	-0.77	0.21	-0.08	0.24	0.82	-0.1	0.04	-0.01	-0.29	-0.08	-0.07
Book Value Per Share	-0.96	0.64	0.09		-0.45	0.21	-0.53	0.64	-0.95	0.21	0.83	0.31	0.38	-0.49	-0.92	-0.48	0.91	0.87	-0.68	0.42	0.86	0.84	-0.81	-0.78	0.85	0.84
Free Cash Flow Yield	0.55	0.01	0.08	-0.45		0.65	0.36	0.01	0.56	0.64	-0.35	0.06	0.48	-0.08	0.62	-0.17	-0.45	-0.8	0.89	0.03	-0.8	-0.71	0.1	0.26	-0.81	-0.81
Operating Cash Flow Per Share	-0.22	0.73	0.44	0.21	0.65		-0.41	0.73	-0.17	1.0	0.37	0.3	0.98	-0.52	-0.11	-0.78	0.08	-0.28	0.5	0.64	-0.29	-0.04	-0.41	-0.55	-0.33	-0.32
Capex To Depreciation	0.74	-0.7	-0.7	-0.53	0.36	-0.41		-0.7	0.71	-0.42	-0.81	-0.37	-0.53	0.57	0.7	0.79	-0.46	-0.41	0.27	-0.85	-0.39	-0.66	0.42	0.79	-0.38	-0.39
Pb Ratio	-0.72	1.0	0.3	0.64	0.01	0.73	-0.7		-0.63	0.74	0.67	0.11	0.86	-0.4	-0.6	-0.71	0.41	0.3	-0.13	0.64	0.28	0.48	-0.54	-0.96	0.23	0.23
Ev To Sales	0.98	-0.63	-0.21	-0.95	0.56	-0.17	0.71	-0.63		-0.19	-0.9	-0.45	-0.35	0.59	0.99	0.56	-0.88	-0.88	0.69	-0.55	-0.87	-0.94	0.79	0.81	-0.86	-0.86
Free Cash Flow Per Share	-0.23	0.74	0.45	0.21	0.64	1.0	-0.42	0.74	-0.19		0.39	0.31	0.98	-0.53	-0.12	-0.79	0.09	-0.27	0.49	0.66	-0.28	-0.03	-0.41	-0.56	-0.32	-0.31
Roic	-0.89	0.67	0.54	0.83	-0.35	0.37	-0.81	0.67	-0.9	0.39		0.55	0.52	-0.76	-0.83	-0.82	0.88	0.65	-0.38	0.82	0.63	0.75	-0.63	-0.77	0.64	0.63
Inventory Turnover	-0.31	0.11	0.28	0.31	0.06	0.3	-0.37	0.11	-0.45	0.31	0.55		0.3	-0.94	-0.43	-0.58	0.5	0.19	0.08	0.59	0.18	0.43	-0.57	-0.17	0.21	0.2
Net Income Per Share	-0.41	0.86	0.43	0.38	0.48	0.98	-0.53	0.86	-0.35	0.98	0.52	0.3		-0.55	-0.29	-0.82	0.23	-0.1	0.33	0.7	-0.11	0.14	-0.49	-0.71	-0.15	-0.15
Days Of Inventory On Hand	0.5	-0.4	-0.48	-0.49	-0.08	-0.52	0.57	-0.4	0.59	-0.53	-0.76	-0.94	-0.55		0.54	0.82	-0.63	-0.24	-0.07	-0.8	-0.23	-0.48	0.64	0.43	-0.25	-0.24
Payables Turnover	0.96	-0.6	-0.11	-0.92	0.62	-0.11	0.7	-0.6	0.99	-0.12	-0.83	-0.43	-0.29	0.54		0.47	-0.81	-0.89	0.75	-0.47	-0.88	-0.98	0.79	0.79	-0.87	-0.87
Capex To Revenue	0.57	-0.71	-0.77	-0.48	-0.17	-0.78	0.79	-0.71	0.56	-0.79	-0.82	-0.58	-0.82	0.82	0.47		-0.51	-0.12	-0.17	-0.97	-0.1	-0.36	0.49	0.68	-0.1	-0.1
Cash Per Share	-0.85	0.41	0.21	0.91	-0.45	0.08	-0.46	0.41	-0.88	0.09	0.88	0.5	0.23	-0.63	-0.81	-0.51		0.82	-0.57	0.49	0.81	0.75	-0.68	-0.55	0.83	0.81
Pocfratio	-0.86	0.3	-0.08	0.87	-0.8	-0.28	-0.41	0.3	-0.88	-0.27	0.65	0.19	-0.1	-0.24	-0.89	-0.12	0.82		-0.94	0.13	1.0	0.9	-0.62	-0.53	1.0	1.0
Interest Coverage	0.69	-0.13	0.24	-0.68	0.89	0.5	0.27	-0.13	0.69	0.49	-0.38	0.08	0.33	-0.07	0.75	-0.17	-0.57	-0.94		0.13	-0.94	-0.8	0.43	0.38	-0.93	-0.94
Capex To Operating Cash Flow	-0.55	0.64	0.82	0.42	0.03	0.64	-0.85	0.64	-0.55	0.66	0.82	0.59	0.7	-0.8	-0.47	-0.97	0.49	0.13	0.13		0.11	0.38	-0.36	-0.63	0.12	0.12
Pfcf Ratio	-0.84	0.28	-0.1	0.86	-0.8	-0.29	-0.39	0.28	-0.87	-0.28	0.63	0.18	-0.11	-0.23	-0.88	-0.1	0.81	1.0	-0.94	0.11		0.89	-0.62	-0.52	1.0	1.0
Days Payables Outstanding	-0.9	0.48	0.04	0.84	-0.71	-0.04	-0.66	0.48	-0.94	-0.03	0.75	0.43	0.14	-0.48	-0.98	-0.36	0.75	0.9	-0.8	0.38	0.89		-0.73	-0.7	0.88	0.89
Income Quality	0.74	-0.54	-0.01	-0.81	0.1	-0.41	0.42	-0.54	0.79	-0.41	-0.63	-0.57	-0.49	0.64	0.79	0.49	-0.68	-0.62	0.43	-0.36	-0.62	-0.73		0.63	-0.59	-0.6
Roe	0.87	-0.96	-0.29	-0.78	0.26	-0.55	0.79	-0.96	0.81	-0.56	-0.77	-0.17	-0.71	0.43	0.79	0.68	-0.55	-0.53	0.38	-0.63	-0.52	-0.7	0.63		-0.47	-0.48
Ev To Operating Cash Flow	-0.83	0.23	-0.08	0.85	-0.81	-0.33	-0.38	0.23	-0.86	-0.32	0.64	0.21	-0.15	-0.25	-0.87	-0.1	0.83	1.0	-0.93	0.12	1.0	0.88	-0.59	-0.47		1.0
Pe Ratio	-0.83	0.23	-0.07	0.84	-0.81	-0.32	-0.39	0.23	-0.86	-0.31	0.63	0.2	-0.15	-0.24	-0.87	-0.1	0.81	1.0	-0.94	0.12	1.0	0.89	-0.6	-0.48	1.0

Click cells to compare fundamentals

Neuropace Account Relationship Matchups

Neuropace fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	14.46	5.46	0.81	4.07	4.08	3.87
Ptb Ratio	(4.02)	3.35	1.05	12.9	40.67	42.71
Days Sales Outstanding	74.49	57.28	59.99	68.7	58.7	69.4
Book Value Per Share	(6.2)	3.01	1.41	0.8	0.28	0.29
Free Cash Flow Yield	(0.0364)	(0.1)	(1.02)	(0.0746)	(0.0551)	(0.0578)
Operating Cash Flow Per Share	(0.91)	(1.01)	(1.5)	(0.76)	(0.62)	(0.65)
Stock Based Compensation To Revenue	0.0335	0.0949	0.18	0.15	0.13	0.08
Pb Ratio	(4.02)	3.35	1.05	12.9	40.67	42.71
Ev To Sales	15.1	6.13	2.19	4.9	4.83	9.32
Free Cash Flow Per Share	(0.91)	(1.02)	(1.52)	(0.77)	(0.62)	(0.65)
Roic	(0.4)	(0.2)	(0.44)	(0.29)	(0.27)	(0.28)
Inventory Turnover	1.57	1.5	1.34	1.54	1.56	1.18
Net Income Per Share	(1.51)	(1.56)	(2.17)	(1.27)	(0.93)	(0.98)
Days Of Inventory On Hand	232.08	243.02	272.12	236.61	234.57	273.68
Payables Turnover	11.45	8.53	6.07	7.42	7.05	9.56
Research And Ddevelopement To Revenue	0.38	0.4	0.48	0.32	0.3	0.44
Capex To Revenue	0.001507	0.008499	0.0132	0.002644	0.003041	0.002889
Cash Per Share	1.6	4.73	3.15	2.57	1.81	1.87
Pocfratio	(27.52)	(10.03)	(0.99)	(13.53)	(18.16)	(19.07)
Interest Coverage	(1.14)	(3.2)	(5.42)	(3.19)	(2.46)	(2.59)
Capex To Operating Cash Flow	(0.002869)	(0.0156)	(0.0164)	(0.008781)	(0.007903)	(0.008298)
Pfcf Ratio	(27.44)	(9.87)	(0.98)	(13.41)	(18.16)	(19.07)
Days Payables Outstanding	31.88	42.81	60.16	49.2	51.78	35.62
Income Quality	0.89	0.68	0.78	0.6	0.66	0.81
Roe	0.24	(0.52)	(1.53)	(1.6)	(3.39)	(3.22)
Ev To Operating Cash Flow	(28.75)	(11.28)	(2.71)	(16.29)	(21.5)	(22.57)
Pe Ratio	(16.53)	(6.47)	(0.69)	(8.09)	(12.01)	(12.61)
Ev To Free Cash Flow	(28.67)	(11.1)	(2.66)	(16.15)	(21.5)	(22.57)
Earnings Yield	(0.0605)	(0.15)	(1.46)	(0.12)	(0.0833)	(0.0874)
Net Debt To E B I T D A	(2.12)	(1.08)	(1.73)	(2.38)	(3.61)	(3.8)
Current Ratio	5.69	14.28	8.9	5.71	5.37	5.36
Tangible Book Value Per Share	(6.2)	3.01	1.41	0.8	0.28	0.29
Receivables Turnover	4.9	6.37	6.08	5.31	6.22	4.67
Shareholders Equity Per Share	(6.2)	3.01	1.41	0.8	0.28	0.29
Debt To Equity	(0.36)	0.68	2.01	3.51	9.15	9.61
Capex Per Share	0.002602	0.0157	0.0245	0.006692	0.007696	0.0152
Graham Net Net	(6.54)	2.65	0.35	(0.22)	(0.6)	(0.63)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:

How To Invest In Neuropace

Details

Is Neuropace Stock a good investment?

Details

What is Neuropace's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.93)

Revenue Per Share

2.743

Quarterly Revenue Growth

0.192

Return On Assets

(0.13)

Return On Equity

(1.89)

The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Neuropace Historical Financial Ratios

About Neuropace Financial Ratios Analysis

Neuropace Financial Ratios Chart

Free Cash Flow Yield

Operating Cash Flow Per Share

Capex To Depreciation

Neuropace fundamentals Correlations

Neuropace Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuropace fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Pe Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pfcf Ratio

Days Payables Outstanding	- 0.98	Payables Turnover
Capex To Operating Cash Flow	- 0.97	Capex To Revenue
Roe	- 0.96	Pb Ratio
Roe	- 0.96	Ptb Ratio
Book Value Per Share	- 0.96	Price To Sales Ratio
Ev To Sales	- 0.95	Book Value Per Share